Heat shock protein 90 targeting therapy: state of the art and future perspective

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Heat shock protein 90 (Hsp90) is a molecular chaperone essential for stabilizing over 200 client proteins.
• Hsp90 is vital for the function of numerous oncogenic signaling proteins, contributing to cancer hallmarks.
• The development of Hsp90 inhibitors has been pursued since the 1970s.

Purpose of the Study:

• To provide an overview of the current clinical trial status of Hsp90 inhibitors.
• To discuss future perspectives for novel anticancer strategies utilizing Hsp90 inhibitors.

Main Methods:

• Review of existing literature on Hsp90 inhibitors.
• Analysis of data from Phase II and III clinical trials.
• Exploration of emerging therapeutic approaches targeting Hsp90.

Main Results:

• Multiple Hsp90 inhibitors have advanced to Phase II and III clinical trials.
• Significant research efforts are ongoing to develop Hsp90-targeted cancer therapies.
• Hsp90 inhibition represents a promising avenue for novel anticancer drug development.

Conclusions:

• Hsp90 inhibitors are a key focus in ongoing cancer research and clinical development.
• Further investigation into Hsp90-targeted strategies holds potential for advancing cancer treatment.
• The review highlights the evolving landscape of Hsp90 inhibitor-based anticancer therapies.